Hence, aberrant SOCS1 expression might induce the resistance against IFN-α therapy and cause poor prognosis, which implied that SOCS1 might be a negative prognostic biomarker in the chronic myeloid leukemia treated with IFN-α. The gene discussed is SOCS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.